SKYE   $0.0156  -2.50% Market Closed

Skye Bioscience Inc
Last Events:

2023-08-09 Signal in Stochastic changed from bearish to bearish weakening. The stochastic indicator is in the oversold territory and it heading north. These factors indicate that perhaps the downside trend is coming to an end. Last signal: main and signal line crossing.

2023-08-09 Signal in RSI changed from bearish to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-09 Signal in EMA100 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.

2023-08-09 Trend Power changed from slow to almost flat.

2023-08-06 Trend pattern changed from расходящийся клин с наклоном вверх to восходящий клин.

2023-08-06 Trend Power changed from almost flat to slow.

2023-08-05 Trend Power changed from slow to almost flat.

2023-08-04 Trend pattern changed from канал to расходящийся клин с наклоном вверх.


Current temperature: 1.75
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 1
Target Price Mean 20.00
Mean unverified/preliminary 20.00 / 20.00
Target Price Low / High 20.00 / 20.00
Median / STD DEV 20.00 / 0.00
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total None Sell Sell
rsi None Sell Sell
macd None Sell None
stoch None Sell None
ma20 None Sell None
ma50 Sell None None
ma100 None Sell Sell
Candlestick PatternAug. 17, 2023 Long Legged - consists of a Doji with very long upper and lower shadows. Indicates strong forces balanced in opposition.
ISIN US83086J1016
ceo Mr. Punit S. Dhillon B.A.
Website https://skyebioscience.com
Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.